We designed the Prospective Randomized Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations ( STATCOPE ) as a randomized , controlled trial of simvastatin ( at a daily dose of 40 mg ) versus placebo , with annual exacerbation rates as the primary outcome .